vs
BWX Technologies, Inc.（BWXT）とEncompass Health Corp（EHC）の財務データ比較。上の社名をクリックして会社を切り替えられます
Encompass Health Corpの直近四半期売上が大きい（$1.5B vs $885.8M、BWX Technologies, Inc.の約1.7倍）。BWX Technologies, Inc.の純利益率が高く（10.5% vs 9.5%、差は1.0%）。BWX Technologies, Inc.の前年同期比売上増加率が高い（18.7% vs 9.9%）。Encompass Health Corpの直近四半期フリーキャッシュフローが多い（$116.7M vs $56.8M）。過去8四半期でBWX Technologies, Inc.の売上複合成長率が高い（21.1% vs 8.3%）
BWXテクノロジーズ社（略称BWXT）は米国バージニア州リンチバーグに本社を置き、原子力関連部品及び燃料を世界各国に供給する企業です。原子力発電や関連産業分野の顧客ニーズに応え、高品質な製品を提供しています。
エンコンパスヘルスコーポレーション（旧Amcare、HealthSouth）は米国アラバマ州バーミンガムに本社を置く米国最大の入院リハビリサービス事業者で、39州とプエルトリコに173の入院リハビリ病院を展開し、脳卒中や神経疾患、心肺疾患、脳損傷から回復中の患者に専門的な治療とケアを提供している。
BWXT vs EHC — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $885.8M | $1.5B |
| 純利益 | $93.0M | $146.1M |
| 粗利率 | — | — |
| 営業利益率 | 10.4% | 16.7% |
| 純利益率 | 10.5% | 9.5% |
| 売上前年比 | 18.7% | 9.9% |
| 純利益前年比 | 30.9% | 20.8% |
| EPS（希薄化後） | $1.02 | $1.43 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $885.8M | $1.5B | ||
| Q3 25 | $866.3M | $1.5B | ||
| Q2 25 | $764.0M | $1.5B | ||
| Q1 25 | $682.3M | $1.5B | ||
| Q4 24 | $746.3M | $1.4B | ||
| Q3 24 | $672.0M | $1.4B | ||
| Q2 24 | $681.5M | $1.3B | ||
| Q1 24 | $604.0M | $1.3B |
| Q4 25 | $93.0M | $146.1M | ||
| Q3 25 | $82.1M | $126.5M | ||
| Q2 25 | $78.4M | $142.1M | ||
| Q1 25 | $75.5M | $151.5M | ||
| Q4 24 | $71.0M | $120.9M | ||
| Q3 24 | $69.5M | $108.2M | ||
| Q2 24 | $73.0M | $114.1M | ||
| Q1 24 | $68.5M | $112.5M |
| Q4 25 | — | — | ||
| Q3 25 | 21.8% | — | ||
| Q2 25 | 25.1% | — | ||
| Q1 25 | 24.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 24.4% | — | ||
| Q2 24 | 24.7% | — | ||
| Q1 24 | 24.6% | — |
| Q4 25 | 10.4% | 16.7% | ||
| Q3 25 | 13.1% | 14.9% | ||
| Q2 25 | 13.4% | 16.2% | ||
| Q1 25 | 14.2% | 16.4% | ||
| Q4 24 | 12.4% | 14.3% | ||
| Q3 24 | 14.4% | 13.6% | ||
| Q2 24 | 14.5% | 14.3% | ||
| Q1 24 | 15.4% | 13.6% |
| Q4 25 | 10.5% | 9.5% | ||
| Q3 25 | 9.5% | 8.6% | ||
| Q2 25 | 10.3% | 9.7% | ||
| Q1 25 | 11.1% | 10.4% | ||
| Q4 24 | 9.5% | 8.6% | ||
| Q3 24 | 10.3% | 8.0% | ||
| Q2 24 | 10.7% | 8.8% | ||
| Q1 24 | 11.3% | 8.5% |
| Q4 25 | $1.02 | $1.43 | ||
| Q3 25 | $0.89 | $1.24 | ||
| Q2 25 | $0.85 | $1.39 | ||
| Q1 25 | $0.82 | $1.48 | ||
| Q4 24 | $0.77 | $1.18 | ||
| Q3 24 | $0.76 | $1.06 | ||
| Q2 24 | $0.79 | $1.12 | ||
| Q1 24 | $0.75 | $1.10 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $499.8M | $72.2M |
| 総負債低いほど良い | — | $2.4B |
| 株主資本純資産 | $1.2B | $2.4B |
| 総資産 | $4.3B | $7.1B |
| 負債/資本比率低いほどレバレッジが低い | — | 1.00× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $499.8M | $72.2M | ||
| Q3 25 | $79.6M | $48.7M | ||
| Q2 25 | $37.0M | $99.1M | ||
| Q1 25 | $55.4M | $95.8M | ||
| Q4 24 | $74.1M | $85.4M | ||
| Q3 24 | $35.5M | $147.8M | ||
| Q2 24 | $48.3M | $154.4M | ||
| Q1 24 | $45.9M | $134.4M |
| Q4 25 | — | $2.4B | ||
| Q3 25 | — | $2.4B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $2.3B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | — | $2.7B | ||
| Q1 24 | — | $2.7B |
| Q4 25 | $1.2B | $2.4B | ||
| Q3 25 | $1.2B | $2.4B | ||
| Q2 25 | $1.2B | $2.3B | ||
| Q1 25 | $1.1B | $2.2B | ||
| Q4 24 | $1.1B | $2.1B | ||
| Q3 24 | $1.1B | $2.0B | ||
| Q2 24 | $998.5M | $1.8B | ||
| Q1 24 | $946.2M | $1.7B |
| Q4 25 | $4.3B | $7.1B | ||
| Q3 25 | $3.8B | $6.9B | ||
| Q2 25 | $3.7B | $6.8B | ||
| Q1 25 | $3.1B | $6.6B | ||
| Q4 24 | $2.9B | $6.5B | ||
| Q3 24 | $2.9B | $6.5B | ||
| Q2 24 | $2.8B | $6.4B | ||
| Q1 24 | $2.8B | $6.2B |
| Q4 25 | — | 1.00× | ||
| Q3 25 | — | 1.01× | ||
| Q2 25 | — | 1.02× | ||
| Q1 25 | — | 1.08× | ||
| Q4 24 | — | 1.14× | ||
| Q3 24 | — | 1.20× | ||
| Q2 24 | — | 1.46× | ||
| Q1 24 | — | 1.54× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $127.0M | $346.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $56.8M | $116.7M |
| FCFマージンFCF / 売上 | 6.4% | 7.6% |
| 設備投資強度設備投資 / 売上 | 7.9% | 14.8% |
| キャッシュ転換率営業CF / 純利益 | 1.37× | 2.37× |
| 直近12ヶ月FCF直近4四半期 | $295.3M | $439.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $127.0M | $346.0M | ||
| Q3 25 | $143.2M | $270.8M | ||
| Q2 25 | $159.0M | $270.2M | ||
| Q1 25 | $50.6M | $288.6M | ||
| Q4 24 | $276.9M | $278.8M | ||
| Q3 24 | $32.6M | $267.8M | ||
| Q2 24 | $65.9M | $217.4M | ||
| Q1 24 | $33.0M | $238.8M |
| Q4 25 | $56.8M | $116.7M | ||
| Q3 25 | $94.9M | $83.7M | ||
| Q2 25 | $126.3M | $113.3M | ||
| Q1 25 | $17.3M | $125.5M | ||
| Q4 24 | $224.4M | $80.1M | ||
| Q3 24 | $-7.7M | $120.3M | ||
| Q2 24 | $35.5M | $60.5M | ||
| Q1 24 | $2.6M | $99.4M |
| Q4 25 | 6.4% | 7.6% | ||
| Q3 25 | 11.0% | 5.7% | ||
| Q2 25 | 16.5% | 7.8% | ||
| Q1 25 | 2.5% | 8.6% | ||
| Q4 24 | 30.1% | 5.7% | ||
| Q3 24 | -1.1% | 8.9% | ||
| Q2 24 | 5.2% | 4.6% | ||
| Q1 24 | 0.4% | 7.6% |
| Q4 25 | 7.9% | 14.8% | ||
| Q3 25 | 5.6% | 12.7% | ||
| Q2 25 | 4.3% | 10.8% | ||
| Q1 25 | 4.9% | 11.2% | ||
| Q4 24 | 7.0% | 14.1% | ||
| Q3 24 | 6.0% | 10.9% | ||
| Q2 24 | 4.5% | 12.1% | ||
| Q1 24 | 5.0% | 10.6% |
| Q4 25 | 1.37× | 2.37× | ||
| Q3 25 | 1.74× | 2.14× | ||
| Q2 25 | 2.03× | 1.90× | ||
| Q1 25 | 0.67× | 1.90× | ||
| Q4 24 | 3.90× | 2.31× | ||
| Q3 24 | 0.47× | 2.48× | ||
| Q2 24 | 0.90× | 1.91× | ||
| Q1 24 | 0.48× | 2.12× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
BWXT
| Nuclear Component Program | $436.4M | 49% |
| Nuclear Manufacturing | $134.8M | 15% |
| Cost Plus Fee | $116.1M | 13% |
| Uranium And Nuclear Services | $103.8M | 12% |
| Commercial Operations | $49.0M | 6% |
| Commercial Operations Segment | $33.7M | 4% |
| Transferred At Point In Time | $1.3M | 0% |
EHC
| Medicare | $1.0B | 66% |
| Medicare Advantage | $243.1M | 16% |
| Managed Care | $160.7M | 10% |
| Medicaid | $47.0M | 3% |
| Other Income Source | $44.8M | 3% |
| Other Thirdparty Payors | $11.2M | 1% |
| Workers Compensation | $7.6M | 0% |
| Patients | $4.6M | 0% |
